Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma

ClinicalTrials.gov ID: NCT03406078

Public ClinicalTrials.gov record NCT03406078. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicentre, Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma (SOURCE)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma

Study identification

NCT ID: NCT03406078
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: AstraZeneca; Industry
Enrollment: 150 participants

Conditions and interventions

Conditions

Asthma

Interventions

Tezepelumab Biological
Placebo Other

Biological · Other

Eligibility (public fields only)

Age range: 18 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 4, 2018
Primary completion: Sep 24, 2020
Completion: Sep 24, 2020
Last update posted: Dec 8, 2021

2018 – 2020

United States locations

U.S. sites: 21
U.S. states: 13
U.S. cities: 20

Facility	City	State	ZIP	Site status
Research Site	Bakersfield	California	93301	—
Research Site	Newark	Delaware	19713	—
Research Site	Kissimmee	Florida	34741	—
Research Site	Kissimmee	Florida	34746	—
Research Site	Fall River	Massachusetts	02721	—
Research Site	Ann Arbor	Michigan	48109	—
Research Site	St Louis	Missouri	63141	—
Research Site	The Bronx	New York	10461	—
Research Site	Durham	North Carolina	27705	—
Research Site	Greenville	North Carolina	27834	—
Research Site	Cincinnati	Ohio	45231	—
Research Site	Cleveland	Ohio	44130	—
Research Site	Toledo	Ohio	43617	—
Research Site	Oklahoma City	Oklahoma	73109	—
Research Site	Altoona	Pennsylvania	16602	—
Research Site	Homestead	Pennsylvania	15120	—
Research Site	Philadelphia	Pennsylvania	19140	—
Research Site	Anderson	South Carolina	29621	—
Research Site	North Charleston	South Carolina	29406	—
Research Site	McKinney	Texas	75069	—
Research Site	San Antonio	Texas	78251	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03406078, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 8, 2021 · Synced Sep 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03406078 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →